INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ligand Pharmaceuticals Incorporated

The law firm of Kirby
McInerney LLP is investigating potential claims against Ligand
Pharmaceuticals Incorporated (“Ligand” or the “Company”) (NASDAQ: LGND).
This investigation concerns whether Ligand has violated federal
securities laws and/or engaged in other unlawful business practices.

On January 16, 2019, Citron Research published a report entitled
“Pipeline Ligand Pipe Dream,” detailing sources of Ligand’s future
revenues by drug candidate, showing how roughly 60% of the Company’s
milestone payments stem from just two companies. The report alleges that
some of Ligand’s partners have corporate addresses that are really a
home or UPS box, or do not occupy their supposed address. Following this
news, the price of Ligand shares fell $21.72, or approximately 16.5%, to
close at $110.05 on January 16, 2019.

If you acquired Ligand securities, have information, or would like to
learn more about these claims, please contact Thomas
W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected],
or by filling out this
contact form, to discuss your rights or interests with respect to
these matters without any cost to you.

Kirby
McInerney LLP is a New York-based plaintiffs’ law firm concentrating
in securities, antitrust, and whistleblower litigation. The firm’s
efforts on behalf of shareholders in securities litigation have resulted
in recoveries totaling billions of dollars. Additional information about
the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190117005843/en/